Validated RP-HPLC method for the estimation of nebivolol hydrochloride and valsartan in combined tablet dosage form

Abstract

The intention of this work is to develop a rapid, precise, accurate and sensitive reverse phase liquid chromatographic technique for the simultaneous estimation of Nebivolol and Valsartan in tablet dosage form. The chromatographic method was standardized using Inertsil ODS column (250×4.6mm, 5μm particle size) with UV detection at 278nm and flow rate of 1ml/min. The mobile phase comprises of ACN: Buffer (pH adjusted to 3.5 with dilute Ortho Phosphoric acid) in the fraction of 60:40 v/v. The linearity of proposed method was investigated in the range of 12.5-62.5μg/ml (R²=0.999) for Nebivolol and 200-1000μg/ml(R²=0.999) for Valsartan duly. The limit of detection (LOD) was found to be 0.05μg/ml and 0.81μg/ml for Nebivolol and Valsartan duly. The limit of quantification (LOQ) was found to be 0.15μg/ml and 2.44μg/ml for Nebivolol and Valsartan respectively. The retention time of Nebivolol and Valsartan were ground in to be 4.400min and 2.568min respectively. The method was authentically suggested and % RSD was ground in to be less than 2 indicating high degree of accuracy and precision. Hence proposed method can be successfully graded for the simultaneous estimation of Nebivolol and Valsartan in marketed formulation.